InvestmentPitch Media Video Discusses Voyageur Pharmaceuticals’ Notice of Work with the BC Ministry of Mines, for the Removal of 2,000 Tonnes of Barium Sulfate from its Frances Creek Project
23 Septembre 2022 - 12:00PM
Voyageur Pharmaceuticals (TSXV:VM) (OTCPink:VYYRF) has submitted a
notice of work with the BC Ministry of Mines, for the removal of
2,000 tonnes of barium sulfate from its Frances Creek Project. The
Frances Creek project is one of the company’s three 100% owned
projects in British Columbia with grade suitable for the
pharmaceutical barite marketplace.
A Media Snippet accompanying this announcement is
available by clicking on the image or link below:
For more information, please view the
InvestmentPitch Media video which provides additional information
about this news and the company. The video is available for viewing
on “InvestmentPitch.com” and on
“YouTube”. If these links are not enabled, please
visit www.InvestmentPitch.com and enter “Voyageur”
in the search box.
Upon approval from the BC Ministry of Mines,
Voyageur will excavate small, 2-metre-wide surface trenches, to
remove 1,000 tonnes of barite from the A zone and 1,000 tonnes from
the B zone. This tonnage is expected to allow for complete testing
and modifications to the new barium active pharmaceutical
ingredient or API pilot plant, that the company plans to construct,
with construction tentatively scheduled to begin in 2023.
Upon completion of this work program, a notice of
work for a Small Quarry will be submitted to the BC Ministry of
Mines, with plans for full production in 2024.
With the 2,000 tonnes expected to be a high-grade
sample with low waste, Voyageur anticipates extracting 1,000 to
1,200 tonnes of high purity barium sulfate from this sample, to be
used in barium contrast manufacturing.
To put the number in perspective, 1,000 tonnes of
pharmaceutical grade barium sulfate, can create:
- Approximately 111,111,000 bottles of SmoothX smoothie contrast
media, or
- Approximately 3,000,000 bottles of HDX powdered contrast
media
Contrast materials, which may be taken orally or
rectally, are used to improve pictures of the inside of the body
helping to distinguish or "contrast" selected areas of the body
from surrounding tissue allowing the radiologist to distinguish
normal from abnormal conditions.
SGS Canada completed a Preliminary Economic
Assessment and assigned a NPV of $344 million with an IRR of 137%,
to the Frances Creek project.
The company is designing a new barium API pilot
plant, with the goal of reducing the capital required, from the $36
million over three years, stated in the PEA. Voyageur’s plan is to
build a lower cost production facility, fast track production,
process the 2,000 tonnes of barium sulfate and complete full
feasibility based on live real time sales of product. This is
expected to allow the Frances Creek project to be valued with a NI
43-101 defined reserve.
Voyageur is moving forward with its business plan
of becoming the only fully integrated company in the radiology
medical field, by controlling all primary input costs under the
motto of: "From the Earth to the Bottle".
The shares are currently trading at $0.105. For
more information, please visit www.VoyageurPharmaceuticals.ca,
contact Brent Willis, President and CEO, by email at
brent@vpharma.ca, or Al Deslauriers, CFO, at
albertl@vpharma.ca.
Disclaimer
The information in this InvestmentPitch Media Ltd
video is for the viewers information only. Voyageur Pharma has paid
a fee not exceeding $2,000 in cash to have its current news release
produced in video format. The corporate information is based on
information that is publicly available. Any information provided by
InvestmentPitch Media Ltd., through its media services is not to be
construed as a recommendation or suggestion or offer to buy or sell
securities but is provided solely as an informational media
service. InvestmentPitch Media Ltd makes no warranties or
undertakings as to the accuracy or completeness of this
information. All due diligence should be done by the viewer or
their financial advisor. Investing in securities is speculative and
carries risk.
About InvestmentPitch Media
InvestmentPitch Media leverages the power of
video, which together with its extensive distribution, positions a
company’s story ahead of the 1,000's of companies seeking awareness
and funding from the financial community. The company specializes
in producing short videos based on significant news releases,
research reports and other content of interest to investors.
CONTACT: InvestmentPitch Media Barry Morgan, CFO
bmorgan@investmentpitch.com
Voyageur Pharmaceuticals (TSXV:VM)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Voyageur Pharmaceuticals (TSXV:VM)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024